The synthetic bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide suppresses TNFα-induced liver injury

Journal of Hepatology

Volumn 54, Issue 4, 2011, Pages 674-684

  Pathil, Anita ^a   Warth, Arne ^a   Chamulitrat, Walee ^a   Stremmel, Wolfgang ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Endotoxin; Liver inflammation; Phospholipid homeostasis; TNF ; UDCA LPE

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CASPASE 7; CASPASE 8; DACTINOMYCIN; GALACTOSAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; LIVER PROTECTIVE AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE A2; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; URSODEOXYCHOLYL LYSOPHASPHATIDYLETHANOLAMIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL DEATH; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VIVO STUDY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL DAMAGE; LIVER PARENCHYMA; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; APOPTOSIS; CELL LINE; CHOLAGOGUES AND CHOLERETICS; CYTOKINES; DRUG-INDUCED LIVER INJURY; GALACTOSAMINE; GENE EXPRESSION; HUMANS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED C57BL; PHOSPHATIDYLCHOLINES; PHOSPHOLIPASES A2; PHOSPHOLIPIDS; TUMOR NECROSIS FACTOR-ALPHA; URSODEOXYCHOLIC ACID;

EID: 79952700159     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.07.028     Document Type: Article

References (56)

1. Arvelo MB, Cooper JT, Longo C, Daniel S, Grey ST, Mahiou J, et al. A20 protects mice from D-galactosamine/lipopolysaccharide acute toxic lethal hepatitis. Hepatology 2002;35 (3):535-543. (Pubitemid 34183956)
2. 2+-independent phospholipase A2 but not cytosolic phospholipase A2, which undergoes proteolytic inactivation. J Biol Chem 1998;273 (22):13870-13877.
3. Basanez G, Sharpe JC, Galanis J, Brandt TB, Hardwick JM, Zimmerberg J. Bax-type apoptotic proteins porate pure lipid bilayers through a mechanism sensitive to intrinsic monolayer curvature. J Biol Chem 2002;277 (51):49360-49365. (Pubitemid 36014367)
4. Beyaert R, Heyninck K, Van Huffel S. A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol 2000;60 (8):1143-1151.
5. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112 (12):917-920. (Pubitemid 20193676)
6. Botla R, Spivey JR, Aguilar H, Bronk SF, Gores GJ. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J Pharmacol Exp Ther 1995;272 (2):930-938.
7. Calmus Y, Guechot J, Podevin P, Bonnefis MT, Giboudeau J, Poupon R. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology 1992;16 (3):719-723.
8. Casado M, Diaz-Guerra MJ, Bosca L, Martin-Sanz P. Differential regulation of nitric oxide synthase mRNA expression by lipopolysaccharide and pro-inflammatory cytokines in fetal hepatocytes treated with cycloheximide. Biochem J 1997;327 (Pt 3):819-823. (Pubitemid 27487690)
9. Chamulitrat W, Burhenne J, Rehlen T, Pathil A, Stremmel W. Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent. Hepatology 2009;50 (1):143-154.
10. Cheng JC, Chou CH, Kuo ML, Hsieh CY. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 2006;25 (53):7009-7018. (Pubitemid 44722069)
11. Cui Z, Houweling M. Phosphatidylcholine and cell death. Biochim Biophys Acta 2002;1585 (2-3):87-96. (Pubitemid 36092072)
12. Cunningham TJ, Yao L, Lucena A. Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines' unexpected therapeutic properties. J Inflamm (Lond) 2008;5:17.
13. Esposti MD, Cristea IM, Gaskell SJ, Nakao Y, Dive C. Proapoptotic Bid binds to monolysocardiolipin, a new molecular connection between mitochondrial membranes and cell death. Cell Death Differ 2003;10 (12):1300-1309. (Pubitemid 37536735)
14. Fiorucci S, Mencarelli A, Palazzetti B, Del Soldato P, Morelli A, Ignarro LJ. An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity. Proc Natl Acad Sci USA 2001;98 (5):2652-2657. (Pubitemid 32209537)
15. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957;226 (1):497-509.
16. Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 1979;76 (11):5939-5943. (Pubitemid 10216692)
17. Goto M, Okamoto Y, Yamamoto M, Aki H. Anti-inflammatory effects of 5-aminosalicylic acid conjugates with chenodeoxycholic acid and ursodeoxycholic acid on carrageenan-induced colitis in guinea-pigs. J Pharm Pharmacol 2001;53 (12):1711-1720. (Pubitemid 34044260)
18. Han MS, Park SY, Shinzawa K, Kim S, Chung KW, Lee JH, et al. Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. J Lipid Res 2008;49 (1):84-97.
19. Ikegami T, Matsuzaki Y, Fukushima S, Shoda J, Olivier JL, Bouscarel B, et al. Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells. Hepatology 2005;41 (4):896-905. (Pubitemid 40467587)
20. Ishizaki K, Iwaki T, Kinoshita S, Koyama M, Fukunari A, Tanaka H, et al. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production. Eur J Pharmacol 2008;578 (1):57-64. (Pubitemid 350179748)
21. Kalous M, Rauchova H, Drahota Z. The effect of lysophosphatidylcholine on the activity of various mitochondrial enzymes. Biochim Biophys Acta 1992;1098 (2):167-171.
22. Kishimoto T, Soda Y, Matsuyama Y, Mizuno K. An enzymatic assay for lysophosphatidylcholine concentration in human serum and plasma. Clin Biochem 2002;35 (5):411-416. (Pubitemid 35247952)
23. Kudo H, Takahara T, Yata Y, Kawai K, Zhang W, Sugiyama T. Lipopolysaccharide triggered TNF-alpha-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model. J Hepatol 2009;51 (1):168-175.
24. Kume N, Cybulsky MI, Gimbrone Jr MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992;90 (3):1138-1144.
25. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R, et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 2002;111 (3):331-342.
26. Lacaille F, Paradis K. The immunosuppressive effect of ursodeoxycholic acid: a comparative in vitro study on human peripheral blood mononuclear cells. Hepatology 1993;18 (1):165-172. (Pubitemid 23193632)
27. Leifeld L, Dumoulin FL, Purr I, Janberg K, Trautwein C, Wolff M, et al. Early up-regulation of chemokine expression in fulminant hepatic failure. J Pathol 2003;199 (3):335-344. (Pubitemid 36266856)
28. Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 2006;3 (5):321-331.
29. Li Z, Agellon LB, Vance DE. Phosphatidylcholine homeostasis and liver failure. J Biol Chem 2005;280 (45):37798-37802. (Pubitemid 41642390)
30. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker II S. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res 2003;27 (11):1765-1772. (Pubitemid 37444363)
31. Lin MK, Farewell V, Vadas P, Bookman AA, Keystone EC, Pruzanski W. Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. J Rheumatol 1996;23 (7):1162-1166.
32. Luster MI, Germolec DR, Yoshida T, Kayama F, Thompson M. Endotoxin-induced cytokine gene expression and excretion in the liver. Hepatology 1994;19 (2):480-488. (Pubitemid 24046795)
33. McClain CJ. Tumor necrosis and alcoholic hepatitis. Hepatology 1991;14 (2):394-396.
34. Mi LJ, Mak KM, Lieber CS. Attenuation of alcohol-induced apoptosis of hepatocytes in rat livers by polyenylphosphatidylcholine (PPC). Alcohol Clin Exp Res 2000;24 (2):207-212. (Pubitemid 30117423)
35. Miura T, Ouchida R, Yoshikawa N, Okamoto K, Makino Y, Nakamura T, et al. Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid. J Biol Chem 2001;276 (50):47371-47378.
36. Mourelle M, Guarner F, Malagelada JR. Polyunsaturated phosphatidylcholine prevents stricture formation in a rat model of colitis. Gastroenterology 1996;110 (4):1093-1097. (Pubitemid 26113749)
37. Murch O, Collin M, Sepodes B, Foster SJ, Mota-Filipe H, Thiemermann C. Lysophosphatidylcholine reduces the organ injury and dysfunction in rodent models of gram-negative and gram-positive shock. Br J Pharmacol 2006;148 (6):769-777. (Pubitemid 44079406)
38. Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 1988;2 (8602):72-74.
39. Oneta CM, Mak KM, Lieber CS. Dilinoleoylphosphatidylcholine selectively modulates lipopolysaccharide-induced Kupffer cell activation. J Lab Clin Med 1999;134 (5):466-470. (Pubitemid 29530695)
40. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007;46 (4):1081-1090. (Pubitemid 350144772)
41. Ravichandran KS. "Recruitment signals" from apoptotic cells: invitation to a quiet meal. Cell 2003;113 (7):817-820.
42. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998;101 (12):2790-2799. (Pubitemid 28294588)
43. Sass G, Heinlein S, Agli A, Bang R, Schumann J, Tiegs G. Cytokine expression in three mouse models of experimental hepatitis. Cytokine 2002;19 (3):115-120. (Pubitemid 35216191)
44. Schumann J, Tiegs G. Pathophysiological mechanisms of TNF during intoxication with natural or man-made toxins. Toxicology 1999;138 (2):103-126. (Pubitemid 29484463)
45. Shinzawa K, Tsujimoto Y. PLA2 activity is required for nuclear shrinkage in caspase-independent cell death. J Cell Biol 2003;163 (6):1219-1230. (Pubitemid 38032084)
46. Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005;54 (7):966-971. (Pubitemid 40873911)
47. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006;55 (3):415-424. (Pubitemid 43268283)
48. Treede I, Braun A, Sparla R, Kuhnel M, Giese T, Turner JR, et al. Anti-inflammatory effects of phosphatidylcholine. J Biol Chem 2007;282 (37):27155-27164. (Pubitemid 47501946)
49. Warth A, Kroger S, Wolburg H. Redistribution of aquaporin-4 in human glioblastoma correlates with loss of agrin immunoreactivity from brain capillary basal laminae. Acta Neuropathol 2004;107 (4):311-318. (Pubitemid 38477357)
50. Wilensky RL, Shi Y, Mohler 3rd ER, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008;14 (10):1059-1066.
51. Wissing D, Mouritzen H, Egeblad M, Poirier GG, Jaattela M. Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis. Proc Natl Acad Sci USA 1997;94 (10):5073-5077. (Pubitemid 27214738)
52. Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci USA 1997;94 (4):1441-1446. (Pubitemid 27087870)
53. Yamazaki K, Suzuki K, Nakamura A, Sato S, Lindor KD, Batts KP, et al. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology 1999;30 (1):71-78. (Pubitemid 29300571)
54. Yan JJ, Jung JS, Lee JE, Lee J, Huh SO, Kim HS, et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 2004;10 (2):161-167. (Pubitemid 38524886)
55. Yun MR, Okajima F, Im DS. The action mode of lysophosphatidylcholine in human monocytes. J Pharmacol Sci 2004;94 (1):45-50. (Pubitemid 38197184)
56. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25 (5):923-931. (Pubitemid 40627835)